These findings reveal the important role of METTL3-IGF2BP3 axis in the invasive and metastatic ability of tumor cells in pancreatic cancer and provide a basis for the clinical targeting of IGF2BP3 to inhibit the invasive and metastatic ability of pancreatic cancer. The gene discussed is METTL3; the disease is familial pancreatic carcinoma.